Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies

被引：0

作者：

Jonasch, Eric ^{[1
]}

Call, Justin ^{[2
]}

Kambhampati, Swetha ^{[3
]}

Caimi, Paolo ^{[4
]}

Curti, Brendan ^{[5
]}

Diefenbach, Catherine ^{[6
]}

Heath, Elisabeth ^{[7
]}

Park, Steven ^{[8
]}

Kornblum, Noah ^{[9
]}

Li, Weidong ^{[10
]}

Reimers, Melissa ^{[11
]}

Spurgeon, Stephen ^{[12
]}

Vaishampayan, Ulka ^{[13
]}

Ye, Dingwei ^{[14
]}

Zhang, Li ^{[15
]}

Zhao, Weili ^{[16
]}

Chen, Zhu ^{[17
]}

Hunder, Naomi ^{[17
]}

Ma, Sharon ^{[17
]}

Song, Eric ^{[17
]}

Garmezy, Benjamin ^{[18
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dallas, TX USA

[2] START Mt Region, West Valley, UT USA

[3] City Hope Comprehens Canc Ctr, Duarte, CA USA

[4] Cleveland Clin Fdn, Cleveland, OH USA

[5] Providence Canc Inst, Providence Portland Med Ctr, Providence, RI USA

[6] NYU Langone Hlth, New York, NY USA

[7] Hudson Webber Canc Res Ctr, Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[8] Levine Canc Inst, Charlotte, NC USA

[9] Montefiore Med Ctr, Bronx, NY USA

[10] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China

[11] Washington Univ, Sch Med, St Louis, MO USA

[12] Oregon Hlth & Sci Univ, Portland, OR USA

[13] Univ Michigan, Ann Arbor, MI USA

[14] Fudan Univ, Shanghai Canc Hosp, Shanghai, Peoples R China

[15] Sun Yat Sen Univ, Canc Cetr, Guangzhou, Peoples R China

[16] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai, Peoples R China

[17] ProfoundBio US Co, Woodinville, WA USA

[18] Sarah Cannon Res Inst, Tennessee Oncol, London, England

来源：

ONCOLOGIST | 2023年 / 28卷

关键词：

C-0+ZFASDFD70; ADC; antibody-drug conjugate; exatecan; NHL; renal cell carcinoma; nasopharyngeal carcinoma;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 50 条

[21] A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
Gentry T. King
Keith D. Eaton
Brandon R. Beagle
Christopher J. Zopf
Gilbert Y. Wong
Heike I. Krupka
Steven Y. Hua
Wells A. Messersmith
Anthony B. El-Khoueiry
Investigational New Drugs, 2018, 36 : 836 - 847
[22] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
Charlotte Lemech
Natasha Woodward
Nancy Chan
Joanne Mortimer
Louie Naumovski
Silpa Nuthalapati
Bo Tong
Fang Jiang
Peter Ansell
Christine K. Ratajczak
Jasgit Sachdev
Investigational New Drugs, 2020, 38 : 1815 - 1825
[23] A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors
King, Gentry T.
Eaton, Keith D.
Beagle, Brandon R.
Zopf, Christopher J.
Wong, Gilbert Y.
Krupka, Heike I.
Hua, Steven Y.
Messersmith, Wells A.
El-Khoueiry, Anthony B.
INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 836 - 847
[24] Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR.
Calvo, Emiliano
Cleary, James M.
Moreno, Victor
Gifford, Maryella
Roberts-Rapp, Lisa
Ansel, Peter J.
Mittapalli, Rajendar K.
Lee, Ho-jin
Hu, Beibei
Barch, David
Ocampo, Christopher Joseph
Tolcher, Anthony W.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[25] Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody-drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V001, trial in progress)
Patnaik, Amita
Call, Justin A.
Spreafico, Anna
Nabell, Lisle
Yan, Mingjin
Forero-Torres, Andres
Gillison, Maura L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[26] Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Jang, Sekwon
Powderly, John D.
Spira, Alexander I.
Bakkacha, Ouiam
Loo, Deryk
Bohac, Gerry C.
Sharma, Manish
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[27] ROBUST ANTITUMOR ACTIVITY OF THE ANTIBODY-DRUG CONJUGATE SGN-35 WHEN ADMINISTERED EVERY 3 WEEKS TO PATIENTS WITH RELAPSED OR REFRACTORY CD30 POSITIVE HEMATOLOGIC MALIGNANCIES IN A PHASE 1 STUDY
Younes, A.
Forero-Torres, A.
Bartlett, N. L.
Leonard, J. P.
Kennedy, D. A.
Sievers, E. L.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 205 - 205
[28] A phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors
Zhou, Chenfei
Wang, Bin
Teng, Christina
Yang, Hui
Piha-Paul, Sarina A.
Richardson, Gary
Malalasekera, Ashanya
Sun, Yajun
Wang, Wei
Liu, Jieqiong
Shi, Yan
Zhan, Xianbao
Lemech, Charlotte
JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
[29] First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
Tsimberidou, Apostolia Maria
Vo, Henry Hiep
Beck, Jennifer
Shia, Chi-Sheng
Hsu, Pei
Pearce, Tillman E.
JCO PRECISION ONCOLOGY, 2023, 7
[30] First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors
Garrido-Laguna, Ignacio
Krop, Ian
Burris, Howard A., III
Hamilton, Erika
Braiteh, Fadi
Weise, Amy M.
Abu-Khalaf, Maysa
Werner, Theresa L.
Pirie-Shepherd, Steven
Zopf, Christopher J.
Lakshminarayanan, Mani
Holland, Jaymes S.
Baffa, Raffaele
Hong, David S.
INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (07) : 1798 - 1808

← 1 2 3 4 5 →